Combining Anti-Inflammatory Lipids with Cannabinoids Enhanced Pain Relief in Diabetic Rats
Aspirin-triggered lipoxin A4 reduced diabetic nerve pain in rats, and adding cannabinoid receptor activators amplified the effect.
Quick Facts
What This Study Found
Aspirin-triggered lipoxin A4 (ATL) reduced mechanical hyperalgesia in diabetic rats both acutely and cumulatively. Combining low-dose ATL with CB1 or CB2 receptor agonists (ACEA or JWH-133) produced enhanced pain relief beyond what either achieved alone.
Key Numbers
ATL at 30 ng produced acute pain relief. Cumulative relief at 1, 3, 10, or 30 ng doses. Low-dose ATL (1 or 3 ng) combined with ACEA or JWH-133 (30 mcg/rat) produced augmented pain relief. ATL reduced anxiety-like but not depressive-like behavior in diabetic rats.
How They Did This
Streptozotocin-induced diabetic rats tested with electronic Von Frey for mechanical pain. ATL administered alone (0.3-30 ng) or combined with intrathecal CB1/CB2 agonists. Assessed locomotion, anxiety-like, and depressive-like behaviors.
Why This Research Matters
Current diabetic neuropathy treatments are often inadequate. This study identifies a potential synergy between the body's natural inflammation-resolving molecules and the endocannabinoid system that could lead to more effective combination therapies.
The Bigger Picture
The interaction between pro-resolving lipid mediators and the endocannabinoid system suggests these two systems may naturally work together to control pain and inflammation, opening up new combination treatment strategies.
What This Study Doesn't Tell Us
Animal model only. Streptozotocin-induced diabetes may not fully replicate human diabetic neuropathy. Intrathecal drug delivery not practical for routine clinical use. Short-term assessment only.
Questions This Raises
- ?Would this combination work with plant-derived cannabinoids?
- ?Could oral formulations achieve similar synergy?
- ?What is the mechanism behind the ATL-cannabinoid interaction?
Trust & Context
- Key Stat:
- Low-dose ATL + cannabinoid agonists produced augmented pain relief
- Evidence Grade:
- Animal study with novel drug combination; no human data.
- Study Age:
- 2025 study
- Original Title:
- Aspirin-triggered lipoxin A4 reduces neuropathic pain and anxiety-like behaviours in male diabetic rats: antinociceptive enhancement by cannabinoid receptor agonists.
- Published In:
- European journal of pharmacology, 989, 177254 (2025)
- Authors:
- Ferreira, Matheus Vinícius, Jesus, Carlos Henrique Alves(3), Bonfim da Costa, Jaderson Pedro, Oliveira, Gabrielle, Liebl, Bruno, Verri Junior, Waldiceu, Zanoveli, Janaína Menezes, Cunha, Joice Maria da
- Database ID:
- RTHC-06451
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is aspirin-triggered lipoxin A4?
It's a specialized pro-resolving lipid mediator, meaning it's a natural molecule the body produces (triggered by aspirin) that actively resolves inflammation rather than just blocking it.
Why combine it with cannabinoids?
Each system independently modulates pain. The researchers found that combining low doses of both produced better pain relief than either alone, suggesting the systems interact to enhance each other's effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- thc-and-painkillers-opioid-interactions
- thc-and-muscle-relaxers-combining
- thc-and-ibuprofen-safe-combine-research
Cite This Study
https://rethinkthc.com/research/RTHC-06451APA
Ferreira, Matheus Vinícius; Jesus, Carlos Henrique Alves; Bonfim da Costa, Jaderson Pedro; Oliveira, Gabrielle; Liebl, Bruno; Verri Junior, Waldiceu; Zanoveli, Janaína Menezes; Cunha, Joice Maria da. (2025). Aspirin-triggered lipoxin A4 reduces neuropathic pain and anxiety-like behaviours in male diabetic rats: antinociceptive enhancement by cannabinoid receptor agonists.. European journal of pharmacology, 989, 177254. https://doi.org/10.1016/j.ejphar.2025.177254
MLA
Ferreira, Matheus Vinícius, et al. "Aspirin-triggered lipoxin A4 reduces neuropathic pain and anxiety-like behaviours in male diabetic rats: antinociceptive enhancement by cannabinoid receptor agonists.." European journal of pharmacology, 2025. https://doi.org/10.1016/j.ejphar.2025.177254
RethinkTHC
RethinkTHC Research Database. "Aspirin-triggered lipoxin A4 reduces neuropathic pain and an..." RTHC-06451. Retrieved from https://rethinkthc.com/research/ferreira-2025-aspirintriggered-lipoxin-a4-reduces
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.